At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 37 enrolled

Drug / intervention

Part A: RPL554 +2 moredrug

Likely dose

Part A: RPL554 50mcgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04027439

NCT04027439Phase 2Completed

Compare CT.gov

A Phase II, Randomized Study to Assess the Pharmacokinetics, Safety and Pharmacodynamics of Single and Repeat Doses of RPL554 Administered by Dry Powdered Inhaler in Patients With COPD

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA·interventional·Posted Jul 22, 2019·Updated Sep 26, 2022

In Brief

A Phase 2 clinical trial evaluating Part A: RPL554, Part B: RPL554, and 1 other intervention for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 37 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate 5 doses of RPL554 and placebo, administered by dry powder inhaler (DPI), in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsPulmonary Disease, Chronic Obstructive

CountriesUnited States

CollaboratorsIQVIA Pty Ltd

Timeline

Phase 2CompletedFinished

20192020202120222023202420252026

Enrollment StartDec 2018

Primary CompletionMay 2019

First PostedJul 2019

TodayJul 2026

First PostedJul 22, 2019

Enrollment StartDec 10, 2018

Primary CompletionMay 23, 2019

TodayJul 2, 2026

Enrollment to primary: 5 monthsPosted 6.9 years ago

Interventions

Part A: RPL554drug

1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler

Part B: RPL554drug

Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A

Placebosdrug

Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler. Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A.